Glaxo scores with Olympic anti-doping ads


Throwing its weight--and $31 million--behind the London Olympics qualified GlaxoSmithKline ($GSK) as a good corporate citizen. But as it turns out, the company is getting its money's worth in publicity. Thanks to a savvy marketing move--setting up an anti-doping lab--Glaxo has made so many headlines and newscasts that it would be easier to count which major media haven't run a feature.

Now, Glaxo's Olympic advertising is turning heads. TV ads, posters and billboards have gone up all over the U.K., focusing, again, on the anti-doping lab. And these are no seen-it-all-before Olympic-ring celebrations. Glaxo's TV commercials do take the usual approach of featuring home-country athletes, but forego hackneyed crowd shots and swelling, sentimental music.


Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Take the commercial featuring British track star Marlon Devonish. It begins in a crowded, screaming stadium, but then swoops through Devonish's body with its swarming red blood cells, firing synapses, expanding lungs, and fast-beating heart--interspersed with rapid-fire images of fast-moving forces of nature. A tornado, for instance. When the visual stream shows hair standing on end, ours did, too.

It all ends with an anti-doping tagline: The Crowd Is My Only Drug. The implication: Devonish's body is gearing up for action quite well on its own adrenaline rush, thank you.

Related Articles:
As blockbuster drugs fade, so does TV advertising
Glaxo sales slump in Europe, U.S. on price cuts, generics
FDA cites promos from Astellas, Novartis and GSK

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.